Biopharmaceutical Company Partners With Novavax: COVID-19 Vaccine Co-commercialization
The financial terms of the deal are robust, with Novavax receiving an upfront payment of $500 million from Sanofi.
In the fight against COVID-19 and influenza, Sanofi and Novavax Inc. have announced a landmark co-exclusive licensing agreement. This massive partnership marks a pivotal step forward in addressing ongoing public health needs by co-commercializing COVID-19 vaccines and developing innovative COVID-19-Influenza combination vaccines, which could redefine seasonal vaccination strategies moving forward. $Amesite(AMST.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
